Compare McKesson Corporation (MCK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Twist Bioscience Corp — how do they compare? McKesson Corporation trades at $895 (market cap $105.14B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: McKesson Corporation is far larger — about 13.6× Twist Bioscience Corp's market cap, and McKesson Corporation pays a 0.42% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MCK | TWST | |
|---|---|---|
Market Cap | $105.14B | $7.72B |
Sector | Health | Health |
52-Week High | $995.69 | $124.88 |
52-Week Low | $659.01 | $24.16 |
Enterprise Value | $111.67B | $7.65B |
Dividend Yield | 0.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
